The Globe and Mail reports in its Thursday, April 30, edition that GLP-1 medications like Novo Nordisk's Ozempic, Mounjaro or Wegovy are best known as drugs that reduce cravings and enhance feelings of fullness, but they may overlook the psychological impacts: diminished pleasure from eating. The Globe's Dakshana Bascaramurty writes that as they've grown in popularity, experts and patients alike are realizing the drugs don't solve every food-related issue and in some ways introduce new ones. When it comes to weight loss, it's easy to measure the results of a GLP-1 on a bathroom scale or in the fitting room of a clothing store. But how does one measure the other things lost, like the delight in eating. With GLP-1s, there can sometimes be too much of a good thing. The drugs can be so effective at blocking food noise and reducing the release of dopamine that they can cause anhedonia: a reduced ability to feel pleasure. The anhedonia that can result from taking GLP-1s needs to be better measured and addressed, says obesity researcher Emily Dhurandhar. These impacts are understudied. Much of what researchers like her understand about this side effect has been informed through anecdotal reports.